Polypeptides of FGF-CX

US7253266B2 · kind B2 · utility

Assignee

• Curagen Corporation · US

Inventors

• Richard Shimkets · West Haven, US
• Michael Jeffers · Branford, US
• Sudhirdas Prayaga · Dardenne Prairie, US
• Ferenc Boldog · North Haven, US
• Meijia Yang · East Lyme, US
• Catherine Burgess · Wethersfield, US
• Elma Fernandes · Branford, US
• John Herrmann · Kinderhook, US
• William LaRochelle · Madison, US
• Henri Lichenstein · Guilford, US
• Linda Gorman · Branford, US
• Mei Zhong · Branford, US
• Muralidhara Padigaru · Mumbai, IN
• Carol Pena · New Haven, US
• John Alsobrook · Corrales, US
• Denise Lepley · Branford, US
• Daniel Rieger · Cape Elizabeth, US
• William Grosse · Branford, US

Key dates

• Filing date: Jun 17, 2002
• Grant date: Aug 7, 2007
• Expiry date: Jun 17, 2024

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S435/975
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides FGF-CX, a novel isolated polypeptide, as well as a polynucleotide encoding FGF-CX and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the FGF-CX polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as other uses.